Lupus Nephritis Market to witness growth by 2032, estimates DelveInsight | Aurinia Pharmaceutical, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys

Lupus Nephritis Market to witness growth by 2032, estimates DelveInsight | Aurinia Pharmaceutical, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys
Lupus Nephritis Market

(Albany, USA) DelveInsight’s “Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Lupus Nephritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Lupus Nephritis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Lupus Nephritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Lupus Nephritis market.

 

Request for a Free Sample Report @ Lupus Nephritis Market Forecast

 

Some facts of the Lupus Nephritis Market Report are:

  • According to DelveInsight, Lupus Nephritis market size is expected to grow at a decent CAGR by 2032.
  • The total lupus nephritis market size in the 7MM is approximately USD 1,120 million in 2022 and is projected to increase during the forecast period (2023–2032).
  • Leading Lupus Nephritis companies working in the market are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.
  • Key Lupus Nephritis Therapies expected to launch in the market are BENLYSTA (belimumab), LUPKYNIS (voclosporin), Ianalumab (VAY736), SAPHNELO (anifrolumab), GAZYVA/GAZYVARO (obinutuzumab), Anifrolumab and others.
  • On January 2024, HI-Bio announced a study to evaluate the safety and tolerability of felzartamab plus standard of care in participants with refractory Lupus Nephritis (LN).
  • On March 2024, AstraZeneca announced a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or without concomitant Class V). The total study duration may be up to approximately 116 weeks, including the Screening and Follow-up. Approximately 360 participants will be randomized in a 1:1 ratio to receive anifrolumab or matching placebo throughout during the Treatment Period.

 

Lupus Nephritis Overview

Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects multiple organs, including the kidneys. Lupus nephritis occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and damage. It can present with various symptoms, such as blood or protein in the urine, swelling in the legs or ankles, high blood pressure, and reduced kidney function. Lupus nephritis can progress to chronic kidney disease and end-stage renal failure if left untreated. Diagnosis involves urine and blood tests, imaging studies, and kidney biopsy to assess the severity and type of kidney involvement. Treatment aims to control inflammation, preserve kidney function, and manage symptoms. This may include medications such as corticosteroids, immunosuppressants, and biologic therapies, as well as lifestyle modifications and close monitoring by healthcare providers. Early detection and treatment are crucial in improving outcomes for individuals with Lupus nephritis.

 

Learn more about Lupus Nephritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/lupus-nephritis-market

 

Lupus Nephritis Market

The Lupus Nephritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Lupus Nephritis market trends by analyzing the impact of current Lupus Nephritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Lupus Nephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Lupus Nephritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Lupus Nephritis market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Lupus Nephritis Epidemiology

The Lupus Nephritis epidemiology section provides insights into the historical and current Lupus Nephritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Lupus Nephritis market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Lupus Nephritis Epidemiology @ Lupus Nephritis Market Dynamics

 

Lupus Nephritis Drugs Uptake

This section focuses on the uptake rate of the potential Lupus Nephritis drugs recently launched in the Lupus Nephritis market or expected to be launched in 2019-2032. The analysis covers the Lupus Nephritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Lupus Nephritis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Lupus Nephritis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Lupus Nephritis Pipeline Development Activities

The Lupus Nephritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Lupus Nephritis key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Lupus Nephritis pipeline development activities @ https://www.delveinsight.com/sample-request/lupus-nephritis-market

 

Lupus Nephritis Therapeutics Assessment

Major key companies are working proactively in the Lupus Nephritis Therapeutics market to develop novel therapies which will drive the Lupus Nephritis treatment markets in the upcoming years are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.

 

Learn more about the emerging Lupus Nephritis therapies & key companies @ https://www.delveinsight.com/sample-request/lupus-nephritis-market

 

Lupus Nephritis Report Key Insights

1. Lupus Nephritis Patient Population

2. Lupus Nephritis Market Size and Trends

3. Key Cross Competition in the Lupus Nephritis Market

4. Lupus Nephritis Market Dynamics (Key Drivers and Barriers)

5. Lupus Nephritis Market Opportunities

6. Lupus Nephritis Therapeutic Approaches

7. Lupus Nephritis Pipeline Analysis

8. Lupus Nephritis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Lupus Nephritis Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Lupus Nephritis Competitive Intelligence Analysis

4. Lupus Nephritis Market Overview at a Glance

5. Lupus Nephritis Disease Background and Overview

6. Lupus Nephritis Patient Journey

7. Lupus Nephritis Epidemiology and Patient Population

8. Lupus Nephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Lupus Nephritis Unmet Needs

10. Key Endpoints of Lupus Nephritis Treatment

11. Lupus Nephritis Marketed Products

12. Lupus Nephritis Emerging Therapies

13. Lupus Nephritis Seven Major Market Analysis

14. Attribute Analysis

15. Lupus Nephritis Market Outlook (7 major markets)

16. Lupus Nephritis Access and Reimbursement Overview

17. KOL Views on the Lupus Nephritis Market

18. Lupus Nephritis Market Drivers

19. Lupus Nephritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services